JPRN-jRCT1080225004招募中Unknown
ong Term Follow-Up of Patients Exposed to Lentiviral -Based CAR T-Cell Therapy
ovartis Pharma. K.K.0 个研究点目标入组 14 人开始时间: 2020年1月6日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Other
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All patients who have received a CAR-T therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CAR-T cells or from any CAR-T trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology.
- •Patients who have provided informed consent for the long term follow up study prior to their study participation.
排除标准
- •There are no specific exclusion criteria for this study.
研究者
相似试验
进行中（未招募）
1 期
ong term follow-up study for patients who have been treated with lentivirus-based chimeric antigen receptor (CAR) T-Cell TherapyPatients who have received CAR T-cell therapy in the context of a Novartis and/or Penn treatment trial.MedDRA version: 21.0Level: PTClassification code 10003917Term: B-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10003899Term: B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001673-14-GBovartis Pharma Services AG700
进行中（未招募）
1 期
ong term follow-up study for patients who have been treated with lentivirus-based chimeric antigen receptor (CAR) T-Cell TherapyAll patients who have been treated with chimeric antigen receptor (CAR) T-cell therapy in the context of a prior Novartis sponsored or supported study for any indication.MedDRA version: 21.0Level: PTClassification code 10003917Term: B-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10003899Term: B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001673-14-SEovartis Pharma Services AG900
进行中（未招募）
1 期
ong term follow-up study for patients who have been treated with lentivirus-based chimeric antigen receptor (CAR) T-Cell TherapyEUCTR2014-001673-14-ITOVARTIS PHARMA SERVICES AG700
进行中（未招募）
1 期
ong term follow-up study for patients who have been treated withlentivirus-based chimeric antigen receptor (CAR) T-Cell TherapyAll patients who have been treated with chimeric antigen receptor (CAR)T-cell therapy in the context of a prior Novartis sponsored or supportedstudy for any indication.MedDRA version: 21.0Level: PTClassification code 10003917Term: B-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10003899Term: B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001673-14-ATovartis Pharma Services AG900
进行中（未招募）
1 期
ong term follow-up study for patients who have been treated with lentivirus-based chimeric antigen receptor (CAR) T-Cell TherapyEUCTR2014-001673-14-BEovartis Pharma Services AG700